Intra-Cellular Therapies Inc. News Releases http://ir.intracellulartherapies.com/ Intra-Cellular Therapies Inc. News Releases en Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-present-2019-rbc-capital-markets-global NEW YORK , May 16, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled Thu, 16 May 2019 08:00:00 -0400 Intra-Cellular Therapies Inc. News Releases 10376 Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-presentations-lumateperone-1 NEW YORK , May 15, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the presentation of posters highlighting the lumateperone program in schizophrenia Wed, 15 May 2019 08:00:00 -0400 Intra-Cellular Therapies Inc. News Releases 10366 Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-reports-first-quarter-2019-financial NEW YORK , May 08, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2019 , and Wed, 08 May 2019 07:30:00 -0400 Intra-Cellular Therapies Inc. News Releases 10346 Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-host-first-quarter-2019-financial NEW YORK , May 02, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Thu, 02 May 2019 08:00:00 -0400 Intra-Cellular Therapies Inc. News Releases 10341 Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-mourns-passing-co-founder-and-nobel NEW YORK , April 16, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard , a neuroscientist and Nobel Tue, 16 Apr 2019 08:00:00 -0400 Intra-Cellular Therapies Inc. News Releases 10321 Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-presents-additional-results-long-term NEW YORK , April 15, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced additional results from its open-label safety switching study (Study 303) Mon, 15 Apr 2019 07:00:00 -0400 Intra-Cellular Therapies Inc. News Releases 10316 Intra-Cellular Therapies Announces Presentation of Lumateperone Long-term Open Label Safety Study at the 2019 Congress of the Schizophrenia International Research Society http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-presentation-lumateperone NEW YORK , April 09, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced plans to present analyses from its open-label safety switching study (Study Tue, 09 Apr 2019 08:00:00 -0400 Intra-Cellular Therapies Inc. News Releases 10311 Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-continues-strengthen-its-commercial NEW YORK , March 26, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of John A. Bardi as Senior Vice President for Market Tue, 26 Mar 2019 07:00:00 -0400 Intra-Cellular Therapies Inc. News Releases 10286 Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-present-cowen-and-company-39th-annual NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled Tue, 05 Mar 2019 08:00:00 -0500 Intra-Cellular Therapies Inc. News Releases 10281 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update http://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-reports-fourth-quarter-and-full-year-4 NEW YORK , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, Wed, 27 Feb 2019 07:30:00 -0500 Intra-Cellular Therapies Inc. News Releases 10251